Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandy Jackson

Managing Editor, US Commercial News

San Diego, CA

Mandy reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy.

Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.

Latest From Mandy Jackson

Scrip M&A Podcast: Assessing The Biopharma Deals Environment At Midyear

With the first half of 2024 in the books, Scrip’s Joseph Haas, Mandy Jackson and Kevin Grogan discuss the dealmaking environment at the year’s midpoint and expectations for the second half.

Business Strategies Deals

Finance Watch: Q2 Ends, Q3 Begins With Latest Group Of VC Mega-Rounds

Private Company Edition: June ended with Formation Bio’s $372m series D round and July began with Beacon’s $170m series B. Also, Curie.Bio raised a $380m fund, Freeflow Ventures emerged with $90m across multiple funds and EvolutionaryScale raised a $142m seed round.

Financing Innovation

VC Investment Surges In Q2 As Financial Market Recovery Momentum Builds

Even after removing Xaira’s unusual $1bn seed financing, Evaluate’s data show that biopharma venture capital fundraising increased from the first to the second quarter and from Q2 of last year.

Financing Evaluate Data

Sutro Works Toward A Better Ovarian Cancer ADC

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

BIO Cancer

Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s

The US FDA approved Lilly’s Kisunla (donanemab) for early Alzheimer’s disease and the anti-amyloid antibody will launch into a challenging market primed by Eisai/Biogen’s Leqembi.

Approvals Pricing Strategies

Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics

Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.

Deals Cancer
See All
UsernamePublicRestriction

Register